The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Driffield the two trials found meaningful statistical results for sufferers of ED above 60%. If this is extrapolated to the real world and just half of those 60% start using Eroxon due to the differences highlighted between tablets and Eroxon then just as the panel in today’s webinar said Eroxon would become a leading treatment for ED. Some causes of ED are more severe. I’m not a urologist but the fact that you had surgery and radiation therapy sounds as though you may have suffered from some form of cancer. It would be for a health care professional to advise accordingly on the best treatment after taking advice from the supplier. Clearly as your experience relates eroxon will not work for everyone but that doesn’t mean that it can’t provide relief for a sizeable percentage of ED sufferers.
I’m sorry to hear that Driffield FUM said in an interview with the guardian along time ago that eroxon probably would not work for cases where there is nerve damage. Not sure if this is the case for you but all the same must be disappointing. The company never claimed a 100 percent success rate in their trials.
https://www.cooperconsumerhealth.eu/our-brands/#our-leading
It’s about time but Eroxon now showing as a listed brand on their website. Let’s hope they start investing some money into advertising across Europe for the launch as JB alluded they would.
https://www.gov.uk/government/news/40-community-diagnostic-centres-launching-across-england
It will become interesting when the tenders for a digital pathway for these centres are released
https://healthbusinessuk.net/news/14022023/19-community-diagnostic-centres-open-year
There are 90 already functioning hopefully they will start opening tenders for digital framework.
There seems to be a site first-clinic.jp stocking eroxon although my japanese is non existent and also a middle eastern site. Unfortunately I cannot locate the exact Url on my laptop but found it on my mobile via a picture of eroxon with japenese script. Perhaps the japanese are allowing it into the country with EMA approval.
The spurious one star review has disappeared and all 9 reviews are now on display. They are all favourable. Farmaline probably thought that isolated bad review was bogus so have taken it down. If these kind of decent reviews continue word will quickly spread amongst ED sufferers of the efficacy of eroxon.
I think disappointing would have been a flat rejection of MED3000 as an OTC medical device. It’s a delay and this for myself is a two year investment to realise full potential. Eroxon will find its place in the market. Nothing in this RNS I found alarming just not the FDA approval quite yet that everyone is hoping for.
Apotheke website now showing Eroxon in stock. The stock in these European online pharmacies is gradually being provided. The pre launch has been enacted looking forward to full launch soon.
LB on Advn keeps going on about other gels on the market but none have clinically proven benefit to ED sufferers.